Synthesis and antihyperglycemic activity of chalcone based aryloxypropanolamines
- 1 March 2004
- journal article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry
- Vol. 12 (5), 883-889
- https://doi.org/10.1016/j.bmc.2003.12.026
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Synthetic and biological activity evaluation studies on novel 1,3-diarylpropenonesBioorganic & Medicinal Chemistry, 2001
- A Review of Metabolic and Cardiovascular Effects of Oral Antidiabetic Agents: Beyond Glucose-Level LoweringEuropean Journal of Cardiovascular Risk, 1999
- A selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys.JCI Insight, 1998
- Antioxidant Constituents from Licorice Roots: Isolation, Structure Elucidation and Antioxidative Capacity Toward LDL OxidationFree Radical Biology & Medicine, 1997
- Primary prevention of NIDDM: a practical realityDiabetes/Metabolism Research and Reviews, 1997
- Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patientsDiabetologia, 1996
- Anticancer and antioxidant activity of synthetic chalcones and related compoundsCancer Letters, 1995
- Diabetes, Exercise, and AtherosclerosisDiabetes Care, 1992
- Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent .beta.-adrenergic agonist virtually specific for .beta.3 receptors. A promising antidiabetic and antiobesity agentJournal of Medicinal Chemistry, 1992
- The brown adipocyte β-adrenoceptorProceedings of the Nutrition Society, 1989